Furthermore, conventional drug treatments fail to achieve rigorous metabolic control in more than 50% of T2DM cases, necessitating the search for novel antidiabetic agents that mimic or enhance the properties of insulin as well as protect against diabetic complications [4]. This evidence concerns the gene INS and type 2 diabetes mellitus.